eResearch Issues Initiating Report on Microbix Biosystems Inc.

Jul. 8, 2011 (Baystreet.ca) --

Microbix

Biosystems Inc. (TSX-V: MBX) is a biotechnology company

leveraging its long-standing core virology business to develop products

targeted to large global market opportunities.

Management

has taken a core virology business and used the proceeds this business has

generated over the years and applied them to develop or acquire high-potential,

large-market products to serve a variety of health-science segments. Microbix

has reached the point where a large-market development product has made

substantial progress in moving towards realization. The Company is now at the

threshold and about to reap the benefits.

With

strong growth opportunities in large markets, Microbix is ready to make the

break-through in realizing on its long-term vision. Our 12-month Target Price of

$1.15 per share reflects our expectations that the Company will achieve its

strategic objectives.

To read

the complete Initiating Report, click here: http://www.eresearch.ca/_report/MBX_070711-I.pdf.

eResearch posts all its reports and

articles on its website, www.eresearch.ca,

and subscription is FREE.

About Us: eResearch is a primary source for professional investment research,

focused primarily on small- and mid-cap companies. Our research and analysis is

of institutional quality, and has the potential for reaching millions of global

investors through our extensive electronic distribution network.

Contact:

eResearch: Bob Weir, CFA, Managing Director,

Research Services

Telephone:

(416) 703-6258 Ext 221; E-mail: bweir@eresearch.ca